Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1181 studies found for:    TAG-72
Show Display Options
Rank Status Study
1 Terminated Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma
Conditions: Colorectal Cancer;   Metastases
Interventions: Drug: Unconjugated IDEC-159;   Drug: 111In-IDEC-159;   Drug: 90Y-IDEC-159
2 Completed
Has Results
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicines Including a 12 Week Extension and a 1 Year Open-label Extension Study.
Condition: Acute Gout
Interventions: Drug: Canakinumab 150 mg;   Drug: Triamcinolone acetonide 40 mg;   Drug: Placebo to canakinumab;   Drug: Placebo to triamcinolone acetonide
3 Completed Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome
Condition: Symptoms of Carcinoid Syndrome
Interventions: Drug: Low Dose LX1606 - Day 1 (start);   Drug: Mid-low dose LX1606 - Day 15 (start);   Drug: Mid-high dose LX1606 - Day 29 (start);   Drug: High dose LX1606 - Day 43 (start);   Drug: 4-Week Open Label Dose Extension;   Drug: 72-Week Open Label Dose Extension
4 Terminated
Has Results
Open-Label Study to Evaluate the Long-Term Safety and Efficacy of VI-0521 in Type 2 Diabetic Adults
Condition: Diabetes
Intervention: Drug: VI-0521
5 Completed
Has Results
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchicine Including a 12 Weeks Extension and an Open-label 48 Weeks Extension Study
Condition: Acute Gout
Interventions: Drug: Canakinumab 150 mg;   Drug: Triamcinolone acetonide 40 mg;   Drug: Placebo to canakinumab;   Drug: Placebo to triamcinolone acetonide
6 Completed
Has Results
A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation
Condition: Schizophrenia
Interventions: Drug: Intramuscular ziprasidone mesylate;   Drug: Intramuscular haloperidol
7 Completed
Has Results
Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Condition: Attention Deficit Disorder With Hyperactivity
Interventions: Drug: double blind placebo;   Drug: double blind PR OROS methylphenidate;   Drug: open label PR OROS methylphenidate
8 Completed
Has Results
Multicenter, Safety Study Of Maraviroc
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infection
Intervention: Drug: Maraviroc
9 Completed
Has Results
Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy
Condition: Multifocal Motor Neuropathy
Interventions: Biological: Immune Globulin Intravenous (human), 10%;   Biological: 0.25% human albumin solution (Placebo)
10 Terminated
Has Results
A Study to Evaluate the Effectiveness and Safety of Tapentadol(CG5503) in the Treatment of Acute Pain After Hip Replacement Surgery Compared With Oxycodone and Placebo Followed by a Voluntary Open-Label Extension For Safety
Condition: Arthroplasty
Interventions: Drug: Tapentadol IR (CG5503);   Drug: Placebo;   Drug: Oxycodone HCL IR
11 Completed
Has Results
Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis
Condition: Psoriasis
Interventions: Procedure: Narrow band (310-312 nm) ultraviolet light B phototherapy;   Drug: etanercept
12 Completed
Has Results
Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
Conditions: Schizophrenic Disorders;   Schizoaffective Disorder
Intervention: Drug: Intramuscular olanzapine depot
13 Recruiting Long-Term Safety Of PF-00547659 In Ulcerative Colitis
Condition: Ulcerative Colitis
Intervention: Drug: PF-00547659
14 Completed
Has Results
An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia
Condition: Cervical Dystonia
Intervention: Biological: Botulinum Toxin Type B
15 Completed
Has Results
Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).
Condition: Parkinson Disease
Interventions: Drug: Placebo;   Drug: Pramipexole
16 Recruiting Evaluating the Efficacy, Safety and Tolerability of Tenofovir DF in Pediatric Patients With Chronic Hepatitis B Infection
Condition: Chronic Hepatitis B Infection
Interventions: Drug: Tenofovir DF;   Drug: Placebo to match TDF
17 Completed
Has Results
An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)
Conditions: Multiple Myeloma;   Non-Hodgkin's Lymphoma
Interventions: Drug: bortezomib;   Drug: bortezomib, rifampicin;   Drug: bortezomib, dexamethasone
18 Completed Study of the Effect of Renal Impairment on the Pharmacokinetics of Isavuconazole.
Conditions: Pharmacokinetics of Isavuconazole;   Healthy Volunteers;   Renal Impaired
Intervention: Drug: isavuconazole
19 Completed
Has Results
A Multicenter, Randomized, Open-Label, Parallel-Group Trial to Compare the Efficacy and Safety of the Sufentanil NanoTab PCA System/15 mcg to Intravenous Patient-Controlled Analgesia With Morphine for the Treatment of Acute Post-Operative Pain
Condition: Post-Operative Pain
Interventions: Drug: Sufentanil NanoTab PCA System/15 mcg;   Drug: morphine IV PCA
20 Completed An Open-label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium
Condition: Gastric Ulcer
Intervention: Drug: Esomeprazole Sodium

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years